Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (874)	6/3/1998 11:45:00 AM
From: Zvi Steinberg	Respond to of 1491

Mentioned in Globes too (same lady, different dress): Wednesday, Jun 3, 1998 Sun-Thu at 18:00 (GMT+3) Headlines Pharmos: We Developed Drug Likely to Assist Nerve Gas Victims By Michal Raveh Pharmaceutical company Pharmos announced today that a drug called Dexanabinol, which has been tested on mice by the US army chemical protection research institute, is likely to assist in the treatment of nerve gas victims. Researchers at the US army research institute reported the findings, which showed that administering the drug five minutes after nerve gas injury indicated a decrease in head damage. Pharmos R&D vice president Dr. Anat Begun said that Dexanabinol could be part of standard treatment in nerve gas injuries, combined with Atropine , and that the drug can reduce the damage from exposure to the gas to a minimum. Dexanabinol is currently in Phase II trials for head traumas caused by road accidents. Pharmos plans to start clinical trials on the drug for the treatment of strokes. Published by Israel's Business Arena June 3, 1998

To: Ariella who wrote (874)	6/3/1998 12:05:00 PM
From: Rick Strange	Respond to of 1491

Yosi, I agree with your comment that it would be unethical to test on humans. I'd speculate that since this is an application not intended to treat existing general population conditions that the Army or D.O.D. is probably not under the control of the FDA if they choose test and use HU-211 combined with Atropine to counter nerve gas exposure. We could see this specific application "fast-tracked" years ahead of any FDA controlled indications for HU-211. Atropine is in the backpack of every "grunt" in the field.